{
    "clinical_study": {
        "@rank": "45033", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this group will receive placebo in Step 1 of the study"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study"
            }, 
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this group will receive placebo in Step 2 of the study"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of\n      GSK Biologicals' NTHi candidate vaccine in adults, administered for the first time in\n      humans."
        }, 
        "brief_title": "Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Respiratory Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Influenza, Human", 
                "Respiration Disorders", 
                "Respiratory Tract Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol.\n\n          -  Written informed consent obtained from the subject.\n\n          -  A male or female between, and including, 18 and 40 years of age at the time of the\n             first vaccination.\n\n          -  Healthy subjects as established by medical history, physical examination and\n             laboratory assessment before entering into the study.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination series.\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product other than the study vaccines\n             within 30 days preceding the first dose of study vaccines, or planned use during the\n             study period.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product.\n\n          -  Planned administration/administration of a vaccine/product  not foreseen by the study\n             protocol in the period starting 30 days before the first vaccine dose and ending 30\n             days after the last dose of vaccines.\n\n          -  Previous vaccination with a vaccine containing NTHi antigens.\n\n          -  Chronic administration  of immunosuppressants or other immune-modifying drugs within\n             six months prior to the first vaccine dose, or equivalent. Topical steroids are\n             allowed.\n\n          -  Administration of immunoglobulins and/or any blood products within the 3 months\n             preceding the first dose of study vaccines or planned administration during the study\n             period.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  Laboratory evidence of clinically significant haematological (complete blood cell\n             count [Red Blood Cells (RBC), White Blood Cells (WBC)], WBC differential count,\n             platelets count and haemoglobin level) and biochemical (Alanine Aminotransferase\n             [ALT], Aspartate Aminotransferase [AST], creatinine and lactate dehydrogenase [LDH])\n             abnormalities as per the opinion of the investigator based on the local laboratory\n             normative data.\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal\n             functional abnormality, as determined by physical examination or laboratory screening\n             tests.\n\n          -  History of or current condition preventing intramuscular injection as bleeding or\n             coagulation disorder.\n\n          -  Malignancies within previous 5 years (excluding non-melanic skin cancer) and\n             lymphoproliferative disorders.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions.\n\n          -  History of chronic alcohol consumption and/or drug abuse.\n\n          -  Any other condition that the investigator judges may interfere with study findings."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657526", 
            "org_study_id": "116018"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "Administered intramuscularly (IM) in the deltoid region of non-dominant arm", 
                "intervention_name": "GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group C", 
                "description": "2 doses administered IM in the deltoid region of non-dominant arm", 
                "intervention_name": "GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group D", 
                    "Group B"
                ], 
                "description": "2 doses administered IM in the deltoid region of non-dominant arm", 
                "intervention_name": "Saline placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy adults", 
            "Safety", 
            "Reactogenicity", 
            "Immunogenicity", 
            "Non-typeable H. Influenzae (NTHi)"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Adelaide", 
                    "country": "Australia", 
                    "state": "South Australia", 
                    "zip": "5000"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Healthy Adults", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Therapeutic Goods Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Occurrence of solicited local and general adverse event (AE), in all subjects, in all vaccine groups", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after each vaccination."
            }, 
            {
                "measure": "Occurrence of any unsolicited AE, in all subjects, in all vaccine groups", 
                "safety_issue": "No", 
                "time_frame": "During a 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after each vaccination."
            }, 
            {
                "measure": "Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all vaccine groups", 
                "safety_issue": "No", 
                "time_frame": "At baseline (Screening visit) and after each vaccination."
            }, 
            {
                "measure": "Occurrence of any serious adverse event (SAE), in all subjects, in all vaccine groups", 
                "safety_issue": "No", 
                "time_frame": "From first vaccination to study conclusion (Day 420)."
            }, 
            {
                "measure": "Occurrence of any potential Immune-Mediated Disease (pIMDs) in all subjects, in all vaccine groups", 
                "safety_issue": "No", 
                "time_frame": "From first vaccination to study conclusion (Day 420)."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657526"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Humoral immune response to components of the NTHi vaccine formulations, in all subjects, in all vaccine groups", 
            "safety_issue": "No", 
            "time_frame": "Prior to each vaccination and 30 days post each vaccination."
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}